Key Highlights

● Alphatec plunged on Friday, October 30, 2026, after a third-quarter miss.

● Needham cut its target to $12 from $14.

● TD Cowen lowered its target to $10 from $13.

● Stifel reduced its target to $11 from $13.

Alphatec Holdings (NASDAQ:ATEC) plunged on Friday, October 30, 2026, after its third-quarter results fell short of expectations and the company trimmed its full-year Revenue forecast. The shares were sharply lower before the open and kept falling during the session, making the stock one of the most talked-about names in the Russell 2000. Reports differed on the size of the move at different times of day, but all showed a steep decline.

Three analysts responded by lowering their price targets, according to market data. Needham cut its target to $12 from $14, TD Cowen lowered its target to $10 from $13, and Stifel (NYSE:SF) reduced its target to $11 from $13. Per market data, the firms kept buy-type ratings on the stock, although Stifel's rating was not stated.

What the company reported

Alphatec, based in Carlsbad, California, makes devices, implants and technology used in spine surgery. For the third quarter, it reported adjusted Earnings of $0.09 a share, below the $0.10 analysts had expected. Revenue came in at $221.17 million, short of the $225.44 million consensus, though it was still higher than a year earlier.

The company also lowered its full-year revenue guidance to about $862 million from about $882 million. It now expects its Biologics business, which includes products used alongside implants to help bone heal, to be flat.

Chief executive Pat Miles pointed to that Business as the main reason for the shortfall. "third-quarter revenue fell short of our expectations, primarily due to lower biologics attachment," he said. Attachment refers to how often those products are used together with the company's implants in procedures.

Medical devices in a mixed sector

The selloff in Alphatec came on a day when health care was one of the market's stronger areas. The sector hit a record high, according to market data, as investors rotated out of technology and into defensive stocks. But results-driven moves cut both ways: Stryker (NYSE:SYK), the orthopedics giant, fell after it cut its organic growth outlook, and Canaccord downgraded it to Hold, citing a slowdown in hip and knee markets.

The broader market had its worst session since June. The S&P 500 fell 140.32 points to 7,580.07, the Dow Jones Industrial Average lost 572.25 points to 51,770.31 and the Nasdaq Composite dropped 747.73 points to 25,437.00. The Russell 2000 declined 47.37 points to 2,811.84, though small caps still finished the week higher. Technology led the losses after Intel (NASDAQ:INTC)'s weak outlook and cash-burn warning set off a chip rout.

Reading the target cuts

Price-target cuts after a miss are common, and they reflect analysts' updated models rather than a verdict on the company's long-term future. In Alphatec's case, the lower targets followed both the quarterly shortfall and the reduced annual guidance. Market reports said that the firms kept buy-type ratings even as they trimmed their targets, though it did not state Stifel's rating.

Still, the scale of Friday's decline showed how sensitive investors were to the guidance cut. A lower revenue forecast late in the year leaves less room for the company to make up ground in the fourth quarter.

What to watch

Investors will watch for signs that the biologics business stabilizes and for any update on how the company plans to meet its reduced revenue target. Fourth-quarter results will show whether the lowered guidance proves conservative or whether more adjustments are needed.

Broader conditions also matter. The midterm elections on Tuesday, November 3, and the October jobs report on Friday, November 6, could sway the market, as could Federal Reserve commentary ahead of its December meeting, where markets expect a rate hike.